当前位置: X-MOL 学术Cardiol. Res. Pract. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Effect of Lycopene Supplementation on Some Cardiovascular Risk Factors and Markers of Endothelial Function in Iranian Patients with Ischemic Heart Failure: A Randomized Clinical Trial
Cardiology Research and Practice ( IF 2.1 ) Pub Date : 2022-10-28 , DOI: 10.1155/2022/2610145
Bahareh Karimian 1 , Azam Soleimani 1 , Ghasem Mohammadsharifi 2 , Kiyan Heshmat-Ghahdarijani 3 , Laila Rejali 4 , Davood Shafie 3 , Atefeh Amerizadeh 5 , Masoumeh Sadeghi 5
Affiliation  

Aim. This study aimed to explore if supplementary lycopene tablets may help heart failure (HF) patients improve their lipid profile, BP, and the flow-mediated dilation (FMD) index for endothelial function. Methods. Fifty patients with ischemic HF with a reduced ejection fraction (HFrEF) were randomly assigned to one of two groups: the lycopene group which received 25 mg lycopene tablets once a day for 8 weeks and the control group which received placebo tablets containing starch once a day for 8 weeks. Results. Our results showed that after two months, the amount of triglyceride (TG) and FMD improved significantly compared to the control, TG decreased (219.27 vs. 234.24), and the mean of FMD increased (5.68 vs. 2.95). Other variables, including total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), high-density cholesterol (HDL-C), systolic blood pressure (SBP), and diastolic blood pressure (DBP), showed no improvement. Also, only SBP and FMD showed intragroup improvement in the intervention group. In the intervention group, only SBP and FMD exhibited intragroup improvement. Conclusions. It can be concluded that supplementing with lycopene can enhance endothelial function and reduce the TG levels in ischemic HFrEF patients. However, it had no positive effect on BP, TC, LDL-C, or HDL-C. Trial Registration. This clinical trial was registered at the Iranian Registry of Clinical Trials with IRCT registration number: IRCT20210614051574N4.

中文翻译:

番茄红素补充剂对伊朗缺血性心力衰竭患者某些心血管危险因素和内皮功能标志物的影响:一项随机临床试验

瞄准。本研究旨在探讨补充番茄红素片剂是否可以帮助心力衰竭 (HF) 患者改善血脂、血压和血流介导的内皮功能扩张 (FMD) 指数。方法。50 名伴有射血分数降低 (HFrEF) 的缺血性心力衰竭患者被随机分配到两组中的一组:番茄红素组每天一次服用 25 毫克番茄红素片剂,持续 8 周,对照组每天服用一次含有淀粉的安慰剂片剂8周。结果. 我们的结果显示,两个月后,与对照组相比,甘油三酯 (TG) 和 FMD 的量显着改善,TG 下降(219.27 对 234.24),口蹄疫平均值增加(5.68 对 2.95)。其他变量,包括总胆固醇 (TC)、低密度脂蛋白胆固醇 (LDL-C)、高密度胆固醇 (HDL-C)、收缩压 (SBP) 和舒张压 (DBP),均没有改善。此外,只有 SBP 和 FMD 在干预组中显示出组内改善。在干预组中,只有 SBP 和 FMD 表现出组内改善。结论。可以得出结论,补充番茄红素可以增强缺血性HFrEF患者的内皮功能并降低TG水平。然而,它对 BP、TC、LDL-C 或 HDL-C 没有积极影响。试用注册。该临床试验在伊朗临床试验注册中心注册,IRCT 注册号为:IRCT20210614051574N4。
更新日期:2022-10-28
down
wechat
bug